Lead Investigator: Fan Ge, Guangzhou Medical University
Title of Proposal Research: Organ-specific metastatic landscape dissects programmed death ligand-1 (PD-L1) blockade efficacy in advanced cancer
Vivli Data Request: 8557
Funding Source: None
Potential Conflicts of Interest: None
Summary of the Proposed Research:
For people with advanced cancer that has spread to multiple organs, there is still no perfect treatment that works for everyone. Doctors also have different ideas about how cancer spreads in the body. Some say cancer spreads through the blood, some say it spreads through the lymphatic system, and others say it spreads by directly invading nearby organs. But we don’t know if there are any differences in how cancer spreads in the early stages of the disease, or if there are differences between cancer cells that spread in different ways. We also don’t know if there are differences in how different types of cancer spread in the early stages.
To help answer these questions, scientists want to study how different types of cancer, like lung cancer, breast cancer, kidney cancer, colorectal cancer, bladder cancer, and melanoma, spread in the body. By studying these differences, we can hopefully find better ways to treat advanced cancer that has spread to multiple organs.
Immunotherapy is a powerful treatment that offers hope for many people with advanced cancer. One popular method of immunotherapy is called immunocheckpoint blocking therapy, which helps to activate the body’s immune system to fight cancer cells.
The body’s immune system uses special cells called T cells to recognize and eliminate abnormal cells, including cancer cells. However, T cells can also mistakenly attack normal cells, which can cause autoimmune reactions. To prevent this, the immune system has built-in safeguards called immune checkpoints that keep T cells from going into overdrive.
Unfortunately, some cancer cells take advantage of these immune checkpoints to evade detection and attack from the immune system. One important immune checkpoint is the PD-1/PD-L1 pathway, which is often used by cancer cells to hide from the immune system.
Scientists have developed a way to block the programmed cell death 1 (PD-1)/programmed cell death 1 ligand 1 (PD-L1) pathway using antibodies, which can help to activate the immune system and fight cancer. This therapy has been approved for the treatment of many different types of cancer, including melanoma, lung cancer, lymphoma, bladder cancer, kidney cancer, head and neck cancer, breast cancer, liver cancer, and stomach cancer.
To better understand how cancer spreads and how to improve treatments, we will analyze clinical trial data related to immunotherapy. We will study how cancer spreads to different parts of the body and how this relates to how well immunotherapy works.
The information we gather from this study can help doctors and researchers develop better treatments for people with advanced cancer. It can also provide new insights into how cancer spreads and help us better understand this process.
Requested Studies:
A Phase III, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of Atezolizumab (Anti-PD-L1 Antibody) Compared With Docetaxel in Patients With Non-Small Cell Lung Cancer After Failure With Platinum Containing Chemotherapy
Data Contributor: Roche
Study ID: NCT02008227
Sponsor ID: GO28915
A Phase II, Open-label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of MPDL3280A (Anti−PD-L1 Antibody) Compared With Docetaxel in Patients With Non−Small Cell Lung Cancer After Platinum Failure
Data Contributor: Roche
Study ID: NCT01903993
Sponsor ID: GO28753
A Phase III, Double-Blinded, Randomized, Placebo-Controlled Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFV600 Mutation-Positive Patients With Unresectable Locally Advanced or Metastatic Melanoma
Data Contributor: Roche
Study ID: NCT02908672
Sponsor ID: CO39262
A Phase I/III, Randomized, Double-Blind, Placebo-Controlled Study of Carboplatin Plus Etoposide With or Without Atezolizumab (Anti-PD-L1 Antibody) in Patients With Untreated Extensive-Stage Small Cell Lung Cancer
Data Contributor: Roche
Study ID: NCT02763579
Sponsor ID: GO30081
A Phase III, Open-Label, Randomized Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Bevacizumab Versus Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma
Data Contributor: Roche
Study ID: NCT02420821
Sponsor ID: WO29637
A Phase III Multicenter, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Atezolizumab (MPDL3280A, Anti-PD-L1 Antibody) in Combination With Carboplatin+Nab-Paclitaxel for Chemotherapy-Naive Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer
Data Contributor: Roche
Study ID: NCT02367781
Sponsor ID: GO29537
A Phase III, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of Atezolizumab (Anti-PD-L1 Antibody) Compared With Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer After Failure With Platinum-Containing Chemotherapy
Data Contributor: Roche
Study ID: NCT02302807
Sponsor ID: GO29294
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Data Contributor: Lilly
Study ID: NCT01183780
Sponsor ID: 13856
A Phase II, Randomized Study of Atezolizumab (Anti-PD-L1 Antibody) Administered as Monotherapy or in Combination With Bevacizumab Versus Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma
Data Contributor: Roche
Study ID: NCT01984242
Sponsor ID: WO29074
A Multistage, Phase II Study Evaluating the Safety and Efficacy of Cobimetinib Plus Paclitaxel, Cobimetinib Plus Atezolizumab Plus Paclitaxel, or Cobimetinib Plus Atezolizumab Plus Nab-Paclitaxel as First-Line Treatment for Patients With Metastatic Triple-Negative Breast Cancer
Data Contributor: Roche
Study ID: NCT02322814
Sponsor ID: WO29479
A Randomized, Two-Arm, Open-Label, Multicenter Phase II Trial Assessing the Efficacy and Safety of Pertuzumab Given in Combination With Trastuzumab Plus an Aromatase Inhibitor in First Line Patients With HER2-Positive and Hormone Receptor-Positive Advanced (Metastatic or Locally Advanced) Breast Cancer
Data Contributor: Roche
Study ID: NCT01491737
Sponsor ID: MO27775